Aug 4, 2007|
The mid-week shocker!
Facing the wrath of the sub-prime woes in the US markets, the Indian indices plunged sharply on Wednesday and this resulted in them ending lower for yet another time on the bourses. For the week ended August 3, 2007, both the indices edged lower by 1% each.
The BSE-Sensex managed to close in the positive for four days out of five. Surprising, especially since both the benchmark indices ended in the negative for the week. But not when one considers the fact that the week was witness to one of the biggest intraday declines ever. Coming on the back of a huge sell off across the globe, especially in the US markets, Sensex edged lower by more than 600 points on Wednesday and NSE-Nifty too, declined by more than 180 points. As Foreign Institutional Investors (FIIs) chose to mostly stay away for the remaining days of the week, negating this huge decline was always going to be difficult and with most of the corporate results also not giving any positive surprises, indices closed the week in the red.
As far as institutional activity is concerned, between 27th July and 2nd August, while FIIs turned out to be net sellers to the tune of Rs 16 bn, MFs bough equities worth Rs 8 bn.
On the sectoral indices front, it was largely a mixed trend as indices like 'Bankex' and 'FMCG' edged higher, while 'IT' and 'Auto' witnessed declines. With heavyweights like 'SBI' and 'Auto' witnessed declines. With heavyweights like 'Hindustan Unilever' witnessing strong gains, the optimism also rubbed on their respective sectoral indices, thus making them inch higher. On the other hand, majors like 'M&M' and 'Tata Motors' edged significantly lower during the week and this impacted the performance of the auto index.
||As on July 27
||As on August 3
|BSE OIL AND GAS
Let us have a look at some of the key stock/sector specific developments during the week:
FMCG major Hindustan Unilever (HUL) reported a strong performance for the first quarter ended June 2007. While the topline grew by 13% YoY, the bottomline registered an impressive 30% YoY growth. Growth in the topline was largely driven by strong performances by all the business segments. While sales of soaps and detergents grew by 14% YoY, that of processed foods, beverages and ice creams grew by 38% YoY, 21% YoY and 24% YoY respectively. The board of directors of the company has announced a share buyback scheme at a maximum price of Rs 230 per share. The buyback would result in the promoter stake going up marginally, as they would not be offering their shares under the scheme. The stock closed 5% higher for the week while peer ITC was down 2%.
Top gainers during the week (BSE A)
Tata Motors registered a growth of 5% YoY in the standalone topline led by 1% YoY growth in volumes during 1QFY08. As far as exports are concerned, a strong 42% YoY growth in M&HCV segment helped total exports grow by 6% YoY. Forex gains led to EBITDA margin expansion of 130 basis points. Excluding the same, margins contracted 210 basis points and operating profits fell 16% YoY. Modest rise in interest expense as well as depreciation charges led to a 22% YoY growth in the bottomline and 110 basis point expansion in net margins. Consolidated revenues grew 13% YoY and net profits were up 30% YoY. The stock ended 6% lower for the week, while M&M was down 13%.
Top losers during the week (BSE A)
July 27 (Rs)
Aug 3 (Rs)
||1,265 / 299
||157 / 77
||306 / 185
||410 / 267
||237 / 100
Pharma stocks also edged lower for the week. While GSK Pharma an Cipla were down marginally, Dr Reddy's declined nearly 3%. Decline in Dr Reddy's was despite the fact that the lead anti-diabetic molecule 'Balaglitazone', which the company is developing in partnership with Rheoscience, has entered Phase III clinical trials. There trials will investigate the safety and efficacy of 'Balaglitazone', as an oral anti-diabetic drug. A complete Phase III programme has been designed in which the glucose lowering effects of 'Balaglitazone' will be tested either alone, or in combination with a number of other oral agents. 'Balaglitazone' is being developed under a co-development agreement between the company and Rheoscience. Rheoscience will retain the marketing rights for the European Union and China and Dr Reddy's will retain the marketing rights in the territories of the United States and rest of the world. Rheoscience shall obtain all necessary regulatory approvals on behalf of Dr Reddy's in the United States.
The current phase of heightened volatility is likely to continue, as while stretched valuations are likely to keep some investors at bay, ample liquidity that still exists in the system is likely to make the others take a plunge. We would side with the former lot as paying too much for future growth is not our idea of investing with an adequate margin of safety. Only time will tell, who will be proven right eventually.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407